It is therefore important to define possible albuminuria-lowering and renal protective effects of SGLT2 inhibitors in patients with non-diabetic kidney disease, where hyperglycaemia is not implicated in kidney disease progression. This evidence concerns the gene SLC5A2 and diabetic kidney disease.